secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001437749-24-000419
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen receives EPO notice of intention to grant AV-101 patent for neuropathic pain
--------------------------------------------------------------------------------

- European Patent Office issued Notice of Intention to Grant patent for AV-101 to treat neuropathic pain.
- Patent will not expire until at least 2034; adds to global AV-101 portfolio.
- Preclinical data show AV-101 similar efficacy to gabapentin and pregabalin with better side effect profile.
- Phase 1 data demonstrate AV-101 well-tolerated with no meaningful difference vs placebo.
- Vistagen plans to seek strategic collaborations to advance AV-101 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924000419/0001437749-24-000419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924000419/vtgn20240103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-000419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer